Efficacy and safety of omalizumab in nasal polyposis: POLYP 1 and POLYP 2 trials
Gevaert P, Omachi TA, Corren J, et al.
J Allergy Clin Immunol · 2020
Grade ARCTn=265
Key Findings
- ●Significant NPS reduction vs placebo
- ●Improved nasal congestion and SNOT-22
- ●FDA approval for CRSwNP 2020
- ●Benefit correlated with baseline IgE
Referenced in (1 disease)
ID: pmid-32524991DOI: 10.1016/j.jaci.2020.05.032PMID: 32524991